The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-03. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
==== Collaboration ==== BTS has collaborated with Starbucks to help support the youth in South Korea. Starbucks prepared limited edition merchandise and beverages that have the same shade of purple reminiscent of a starry night, while playing one of BTS songs "Make It Right" in the store. Through this event, Starbucks raised funds to support The Beautiful Foundation.
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU. It was patented in 1967 and approved for medical use in 1972.
=== State offices, regulations === Anti–money laundering office of the Philippines Anti-Money Laundering Office (Thailand) AMLCFT regulation in the United States US Anti–money laundering program (Patriot Act, Title III, Subtitle B Sec.352) Russian Federal Financial Monitoring Service ("Rosfinmonitoring") Australian Transaction Reports and Analysis Centre or AUSTRAC, Australian government agency, Australia's anti–money laundering and counter–terrorism financing regulator
Signs and symptoms of methemoglobinemia (methemoglobin level above 10%) include shortness of breath, cyanosis, mental status changes (~50%), headache, fatigue, exercise intolerance, dizziness, and loss of consciousness. People with severe methemoglobinemia (methemoglobin level above 50%) may exhibit seizures, coma, and death (level above 70%). Healthy people may not have many symptoms with methemoglobin levels below 15%. However, people with co-morbidities such as anemia, cardiovascular disease, lung disease, sepsis, or who have abnormal hemoglobin species (e.g. carboxyhemoglobin, sulfhemoglobinemia or sickle hemoglobin) may experience moderate to severe symptoms at much lower levels (as low as 5–8%).
Sources: en.wikipedia.org
Technetium-99m's short half-life of 6 hours makes storage impossible and would make transport expensive (not impossible; fluorine-18 with its shorter life is transported). Instead, its parent nuclide 99Mo is supplied to hospitals after its extraction from the neutron-irradiated uranium targets and its purification in dedicated processing facilities. It is shipped by specialised radiopharmaceutical companies in the form of technetium-99m generators worldwide or directly distributed to the local market. The generators, colloquially known as moly cows, are devices designed to provide radiation shielding for transport and to minimize the extraction work done at the medical facility. A typical dose rate at 1 metre from the 99mTc generator is 20-50 μSv/h during transport. These generators' output declines with time and they must be replaced weekly, since the half-life of 99Mo is still only 66 hours. Molybdenum-99 spontaneously decays to excited states of 99Tc through beta decay. Over 87% of the decays lead to the desired 99mTc. A β− electron and a νe electron antineutrino are emitted in the process (99Mo → 99mTc + β− + νe). The β− electrons are easily shielded for transport, and 99mTc generators are only minor radiation hazards, mostly due to secondary X-rays produced by the electrons (also known as bremsstrahlung). At the hospital, the 99mTc that forms through 99Mo decay is chemically extracted from the technetium-99m generator.
=== Comprehensive Drug Abuse and Control Act === The original act, passed in 1970, allowed governments to attain funds, drugs, and equipment seized during raids through civil court hearings and drug convictions. Over the years, the list of items allowed to be seized grew in size. In 1984, the Act was amended to allow federal law enforcement agencies to "retain and use any and all proceeds from asset forfeitures, and to allow state and local police agencies to retain up to 80 percent of the assets value." The law now allowed police units to seize cars, cash, and property from drug raids, even without a conviction. "Because those who were targeted were typically poor or of moderate means, they often lacked resources to hire an attorney or pay the considerable court costs. As a result, most people who had their property seized did not challenge the government's action, especially because the government could retaliate by filing criminal charges." Between 1989 and 1992, federally funded state and local police agencies seized over $1 billion in assets. That did not include the DEA or other federally funded enforcement agencies.
Beginning in 1939, Drew traveled every year to Tuskegee, Alabama, to attend the annual free clinic at the John A. Andrew Memorial Hospital. For the 1950 Tuskegee clinic, Drew drove along with three other black physicians. Drew was driving around 8 a.m. on April 1. Still fatigued from spending the night before in the operating theater, he lost control of the vehicle. After careening into a field, the car somersaulted three times. The three other physicians sustained minor injuries. Drew was trapped with severe wounds; his foot was wedged beneath the brake pedal. When reached by emergency technicians, he was in shock and barely alive due to severe leg injuries. Drew was taken to Alamance General Hospital in Burlington, North Carolina. He was pronounced dead a half hour after he first received medical attention. Drew's funeral was held on April 5, 1950, at the Nineteenth Street Baptist Church in Washington, D.C. Despite a popular myth to the contrary, once repeated on an episode ("Dear Dad... Three") of the TV series M*A*S*H and in the novels Carrion Comfort, The 480, and The Human Stain, Drew's death was not the result of his having been refused hospital access because of his race. According to John Ford, one of the passengers in Drew's car, Drew's injuries were so severe that virtually nothing could have been done to save him. Ford added that a blood transfusion might have actually killed Drew sooner.
The growth solution requires a low concentration of a metal precursor, ligands that will readily exchange with preexisting seed ligands, and a weak or very low concentration of reducing agent. The reducing agent must not be strong enough to reduce metal precursor in the growth solution in the absence of seeds. Otherwise, the growth solution will form new nucleation sites instead of growing on preexisting ones (seeds). Growth is the result of the competition between surface energy (which increases unfavorably with growth) and bulk energy (which decreases favorably with growth). The balance between the energetics of growth and dissolution is the reason for uniform growth only on preexisting seeds (and no new nucleation). Growth occurs by the addition of metal atoms from the growth solution to the seeds, and ligand exchange between the growth ligands (which have a higher bonding affinity) and the seed ligands. Range and direction of growth can be controlled by nanoseed, concentration of metal precursor, ligand, and reaction conditions (heat, pressure, etc.). Controlling stoichiometric conditions of growth solution controls ultimate size of particle. For example, a low concentration of metal seeds to metal precursor in the growth solution will produce larger particles. Capping agent has been shown to control direction of growth and thereby shape. Ligands can have varying affinities for binding across a particle. Differential binding within a particle can result in dissimilar growth across particle.
Initially, President Eisenhower was worried that a satellite passing above a nation at over 100 kilometers (62 mi) might be seen as violating that nation's airspace. He was concerned that the Soviet Union would accuse the Americans of an illegal overflight, thereby scoring a propaganda victory at his expense. Eisenhower and his advisors were of the opinion that a nation's airspace sovereignty did not extend past the Kármán line, and they used the 1957–58 International Geophysical Year launches to establish this principle in international law. Eisenhower also feared that he might cause an international incident and be called a "warmonger" if he were to use military missiles as launchers. Therefore, he selected the untried Naval Research Laboratory's Vanguard rocket, which was a research-only rocket. This meant that von Braun's team was not allowed to put a satellite into orbit with their Jupiter-C rocket, because of its intended use as a future military vehicle. On September 20, 1956, von Braun and his team did launch a Jupiter-C that was capable of putting a satellite into orbit, but the launch was used only as a suborbital test of reentry vehicle technology.
Sources: en.wikipedia.org
Pakistan's diverse geography and climate host a wide array of wildlife. Covering 881,913 km2 (340,509 sq mi), Pakistan ranks as the 33rd-largest nation by total area, but this varies based on Kashmir's disputed status. Pakistan boasts a 1,046 km (650 mi) coastline along the Arabian Sea and the Gulf of Oman, and shares land borders totalling 6,774 km (4,209 mi), including 2,430 km (1,510 mi) with Afghanistan, 523 km (325 mi) with China, 2,912 km (1,809 mi) with India, and 909 km (565 mi) with Iran. It has a maritime border with Oman and is separated from Tajikistan via the narrow strip of the Wakhan Corridor. Situated at the crossroads of South Asia, the Middle East, and Central Asia, Pakistan's location is geopolitically significant. Geologically, Pakistan lies at the interaction of the Indian and Eurasian tectonic plates within the Indus–Tsangpo Suture Zone, a region of high seismic activity. The collision between these two plates occurs in northwest Pakistan, particularly in Khyber Pakhtunkhwa. Sindh and Punjab are located on the north-western corner of the Indian Plate, while Balochistan and much of Khyber Pakhtunkhwa lie along its north-western margin. Northern areas of Pakistan, including Azad Kashmir, lie along the northern edge of the Indian Plate and are prone to powerful earthquakes.
Due to use of the drug for date rape and recreation, in 1998 Roche modified the formulation to give lower doses, make it less soluble, and add a blue dye for easier detection in drinks. It was never marketed in the United States, and by 2016 had been withdrawn from the markets in Spain, France, Norway, Germany, and the United Kingdom.
== History == In 1939, the American microbiologist René Dubos discovered the soil microbe Bacillus brevis. He observed the ability of the microbe to decompose the capsule of pneumococcus bacterium, rendering it harmless. From the soil microbe B. brevis, he isolated tyrothricin, which had a high toxicity to a large range of bacteria. Tyrothricin was later found to be a mixture of the peptides gramicidin and tyrocidine. These were observed to have toxic effects in red blood cells and reproductive cells in humans, however, if applied externally as an ointment tyrocidine could also be used as a potent antimicrobial agent. Dubos's discovery helped revive interest in research on penicillin.
=== Autologous fat transplant === This variation of the procedure uses the patient's own fat cells, and therefore is non-allergenic and non-immunogenic. The fat cells are taken from the abdominal wall by suction. Then they are purified and put into a saline solution before injection. When used in other fields such as urology or facial surgery, autologous fat transplants have very rarely been reported to cause fat embolism and stroke. This material is also subject to rapid digestion and migration.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.